Decheng Capital LLC Acquires Shares of 9,684 Grail, Inc. (NASDAQ:GRAL)

Decheng Capital LLC acquired a new stake in Grail, Inc. (NASDAQ:GRAL - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 9,684 shares of the company's stock, valued at approximately $173,000. Grail comprises approximately 0.0% of Decheng Capital LLC's portfolio, making the stock its 27th largest position.

Other institutional investors have also recently modified their holdings of the company. Crcm LP purchased a new stake in Grail during the fourth quarter valued at about $65,061,000. Primecap Management Co. CA acquired a new position in shares of Grail in the 4th quarter valued at approximately $37,118,000. Vanguard Group Inc. bought a new position in Grail during the 4th quarter valued at $25,902,000. Arbiter Partners Capital Management LLC acquired a new stake in shares of Grail in the 4th quarter valued at about $14,827,000. Finally, Geode Capital Management LLC acquired a new position in Grail in the fourth quarter worth $7,920,000.

Insider Activity

In other Grail news, CEO Robert P. Ragusa sold 7,625 shares of the business's stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $31.21, for a total transaction of $237,976.25. Following the sale, the chief executive officer now directly owns 828,662 shares of the company's stock, valued at $25,862,541.02. The trade was a 0.91 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Aaron Freidin sold 1,816 shares of the stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $31.20, for a total value of $56,659.20. Following the completion of the sale, the chief financial officer now directly owns 335,170 shares of the company's stock, valued at approximately $10,457,304. The trade was a 0.54 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 11,550 shares of company stock worth $360,436.

Analyst Ratings Changes

GRAL has been the subject of a number of analyst reports. Canaccord Genuity Group began coverage on shares of Grail in a research note on Monday, April 21st. They set a "buy" rating and a $32.00 target price for the company. Morgan Stanley increased their target price on shares of Grail from $16.00 to $20.00 and gave the company an "equal weight" rating in a research note on Tuesday, March 18th.

Grail Stock Down 6.3 %

Grail stock traded down $2.32 on Wednesday, reaching $34.49. 1,023,563 shares of the stock were exchanged, compared to its average volume of 1,224,020. The firm has a fifty day moving average price of $30.61 and a two-hundred day moving average price of $24.66. Grail, Inc. has a twelve month low of $12.33 and a twelve month high of $63.99.

Grail (NASDAQ:GRAL - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The company reported ($1.86) EPS for the quarter, topping analysts' consensus estimates of ($4.41) by $2.55. The business had revenue of $38.25 million for the quarter, compared to analyst estimates of $35.33 million. As a group, analysts forecast that Grail, Inc. will post -15.15 earnings per share for the current year.

Grail Profile

GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.